ArticleRSC advances2024
Exploitation of the multitarget role of new ferulic and gallic acid derivatives in oxidative stress-related Alzheimer's disease therapies: design, synthesis and bioevaluation.
Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Exploring the Therapeutic Potential ofFood science & nutrition · 2026Article
- Neuroprotective effects of gallic acid in an MPP⁺-induced SH-sy5y cell model of parkinson's disease.Molecular biology reports · 2026Article
- Phenolic Composition Profile and Antidiabetic Activities of Jack Bean [Preventive nutrition and food science · 2026Article
- Structural Modification of Phenolic Acids: Modern Approaches to Synthesis and Study of Structure and Activity.International journal of molecular sciences · 2026Review
- Article
- Pistagremic acid from Pistacia integerrima as a natural multi-target candidate tackling crucial enzymes involved in Alzheimer's disease.Journal of computer-aided molecular design · 2026Article
- Design, Synthesis, SwissADME Profile DFT Studies,Current medicinal chemistry · 2026Article
- Antioxidant, Anti-Inflammatory, and Oral Bioavailability of Novel Sulfonamide Derivatives of Gallic Acid.Antioxidants (Basel, Switzerland) · 2025Article
- Article
- Multipotent Effect of Clozapine on Lipopolysaccharide-Induced Acetylcholinesterase, Cyclooxygenase-2,5-Lipoxygenase, and Caspase-3: In Vivo and Molecular Modeling Studies.Molecules (Basel, Switzerland) · 2025Article
- Article
- Antileishmanial potential of thiourea-based derivatives: design, synthesis and biological activity.RSC advances · 2024Article
- Article
- Pregnenolone derivatives for the treatment of Alzheimer's disease: synthesis, andRSC advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoamine oxidases (MAOs) inhibitors could decrease reactive oxygen species (ROS) generation, enhance mono-aminergic neural transmission, and have major therapeutic benefits for the treatment of Alzheimer's disease (AD). Following the conjunction of ferulic acid (FA)/gallic acid (GA) with sulfonamide, alanine and 2-aminobenzothiazole, we planned to assess the radical scavenging and antioxidant properties of synthesized analogs by using 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) and ferric ion reducing antioxidant power (FRAP) assays. GA analog 28 was identified as the most potent antioxidant compound with IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.